Acneiform eruption / acneiform dermatitis / acneiform rash

• (2023): Yuan C+, J Cosmet Dermatol Mar, Online ahead of print [REVIEW]
• (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
• (2017): Tischer B+, Support Care Cancer 25(2), 651
• (2016): Clabbers JM+, Support Care Cancer 24(2), 513
• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
• (2016): Sibaud V+, Clin Exp Dermatol 41(1), 34 (delayed)
• (2015): Lupu I+, J Med Life 8(Spec Issue), 57
• (2015): Melosky B+, Curr Oncol 22(2), 123
• (2015): Nakahara T+, Onco Targets Ther 8, 259
• (2012): Requena C+, Cutis 90(2), 77
• (2012): Thaler J+, BMC Cancer 12, 438

Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)

• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]

Cutaneous toxicity / skin toxicity

• (2024): Lee JS+, Acta Derm Venereol 104, adv40555
• (2022): Lu CW+, J Eur Acad Dermatol Venereol Nov, Online ahead of print
• (2017): Monjazeb S+, Skin Therapy Lett 22(5), 5
• (2017): Stanculeanu DL+, Maedica (Buchar) 12(1), 48
• (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]
• (2014): Sinclair R, Asia Pac J Clin Oncol 10 Suppl 1, 11 [REVIEW]

Desquamation

• (2012): Requena C+, Cutis 90(2), 77

Eczema / eczematous reaction / eczematous eruption

Erosive pustular dermatosis

• (2023): Zhang Y+, Clin Exp Dermatol Sep, Online ahead of print (3 cases / female) (pharmacogenomics)

Erythema

• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54711% [REVIEW]

Erythema dyschromicum perstans / ashy dermatosis

• (2024): Bang AS+, Support Care Cancer 32(6), 354 (16 cases)

Fissures

Granulomas

• (2022): Liu HL+, J Oncol Pharm Pract Sep, Online ahead of print (22 cases)

Hand–foot syndrome (palmar–plantar erythrodysesthesia)

• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
• (2015): Lupu I+, J Med Life 8(Spec Issue), 57

Hypersensitivity

• (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]

Papulopustular eruption

• (2024): Bălăceanu-Gurău B+, Cureus 16(11), e72878
• (2019): Yalici-Armagan B+, Cutan Ocul Toxicol Apr, Epub ahead of print
• (2018): Sanmartin O, Curr Probl Dermatol 53, 93
• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
• (2016): Clabbers JM+, Support Care Cancer 24(2), 513
• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54727% [REVIEW]
• (2012): Hello M+, Rev Med Interne (French) 33(5), 273
• (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Photosensitivity

• (2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]

Pigmentation (Skin) (includes hyperpigmentation)

Pruritus (itching)

• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
• (2016): Clabbers JM+, Support Care Cancer 24(2), 51317%
• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
• (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Rash

• (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
• (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
• (2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
• (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2014): Hirsh V+, Curr Oncol 21(6), 329
• (2014): Vaubel J+, J Eur Acad Dermatol Venereol 28(12), 1685

Rash

• (2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]

Telangiectases

Xerosis / xeroderma

• (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
• (2018): Sanmartin O, Curr Probl Dermatol 53, 93
• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
• (2016): Clabbers JM+, Support Care Cancer 24(2), 51322%
• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54753% [REVIEW]
• (2012): Requena C+, Cutis 90(2), 77
• (2012): Thaler J+, BMC Cancer 12, 438
• (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Alopecia / hair loss

• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]

Curly hair

• (2015): Herink C+, Hautarzt (German) 66(8), 617 (passim)

Hair changes

• (2018): Sanmartin O, Curr Probl Dermatol 53, 93
• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
• (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]

Nail changes

• (2012): Garden BC+, J Am Acad Dermatol 67(3), 400 [REVIEW]
• (2011): Wu PA+, Curr Opin Oncol 23 (4), 343

Nail disorder

• (2014): Prescrire Int 23(151), 180
• (2012): Requena C+, Cutis 90(2), 77

Paronychia

• (2022): Liu HL+, J Oncol Pharm Pract Sep, Online ahead of print (22 cases)
• (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
• (2018): Sanmartin O, Curr Probl Dermatol 53, 93
• (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
• (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5475% [REVIEW]
• (2015): Melosky B+, Curr Oncol 22(2), 123
• (2012): Hello M+, Rev Med Interne (French) 33(5), 273
• (2012): Thaler J+, BMC Cancer 12, 438

Pyogenic granuloma

Mucositis

• (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
• (2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5477% [REVIEW]

Nasal vestibulitis

• (2015): Ruiz JN+, Support Care Cancer 23(8), 2391 [REVIEW]

Oral ulceration

• (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]

Stomatitis (oral mucositis)

• (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2015): Melosky B+, Curr Oncol 22(2), 123

Cardiotoxicity

• (2024): Wang Y+, Front Oncol Jun (e-Collection) [REVIEW]

Hypomagnesemia

• (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
• (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
• (2016): Jiang DM+, Clin Colorectal Cancer 15(3), e117 [REVIEW]

Diarrhea

• (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
• (2023): Cárdenas-Fernández D+, Ther Adv Med Oncol Aug (e-Collection) [REVIEW]
• (2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]
• (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
• (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
• (2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2014): Hirsh V+, Curr Oncol 21(6), 329

Gastrointestinal adverse reaction

• (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]

Vaginal bleeding

• (2022): Yu M+, Front Oncol Jun (e-Collection) 69% (abnormal menstruation)

Myelosuppression / bone marrow suppression / myelotoxicity

• (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]

Ocular adverse effect

• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]

Trichomegaly

• (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5472% [REVIEW]
• (2012): Thaler J+, BMC Cancer 12, 438

Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury

• (2017): Izzedine H+, Nephrol Dial Transplant 32(7), 1089

Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia (cryptogenic organizing pneumonia) / drug-induced interstitial lung disease

• (2023): Kashizaki F+, Clin Lung Cancer Oct, Online ahead of print14% [REVIEW]

Nasopharyngeal necrosis

• (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) (Reported as an adverse reaction event for patients with nasopharyngeal carcinoma following radiotherapy)

Pneumothorax

• (2020): Guo R+, Thorac Cancer 11(7), 2031-2035 (3 cases) (with microwave ablation)

Pulmonary toxicity

• (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
• (2014): Johkoh T+, Clin Lung Cancer 15(6), 448

Adverse effects / adverse reactions

• (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
• (2023): Liao D+, Int Immunopharmacol Feb, Online ahead of print (with immune checkpoint inhibitor)
• (2020): Huang J+, Sci Rep 10(1), 4803 [REVIEW]
• (2020): Zhou JY+, Expert Opin Drug Saf Apr, Epub ahead of print [REVIEW]
• (2019): Zhao Y+, BMJ 367, 15460 [REVIEW]
• (2017): Below J+, Hautarzt (German) 68(1), 12 [REVIEW] (cutaneous)
• (2015): Sharma A+, Perspect Clin Res 6(2), 1091%

Infection

• (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)